Ju Hee Mun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ju Hee Mun has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Bonggi Lee
Department of Food Science and Nutrition, Pukyong National University, Busan, Republic of Korea
1 shared publication Changhyuk Lee
Brain Science Institute
1 shared publication- Cheol-Hui Ryu
Center of Materials Science and Chemical Engineering, Institute for Advanced Engineering, Yongin 17180, Republic of Korea
1 shared publication - Chun Whan Choi
Natural Product Research Team, Biocenter, Gyeonggido Business and Science Accelerator, Gyeonggi-Do, Republic of Korea
1 shared publication - Gyu-Sang Hong
Brain Science Institute, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea
1 shared publication HyunSeon Moon
Brain Science Institute
1 shared publication
Latest Publications
- 20 February 2025
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 16 (5) , 826-843
Enhanced Cognitive and Memory Functions via Gold Nanoparticle-Mediated Delivery of Afzelin through Synaptic Modulation Pathways in Alzheimer’s Disease Mouse Models
Gold nanoparticles (AuNPs) are valuable tools in pharmacological and biological research, offering unique properties for drug delivery in the treatment of neurodegenerative diseases. This study investigates the potential of gold nanoparticles loaded with afzelin, a natural chemical extracted from Ribes fasciculatum, to enhance its therapeutic effects and overcome the limitations of using natural compounds regarding low productivity. We hypothesized that the combined treatment of AuNPs with afzelin (AuNP-afzelin) would remarkably enforce neuroprotective effects compared with the single treatment of afzelin. Central administration of AuNP-afzelin (10 ng of afzelin) indicated improvements in cognition and memory-involved assessments of behavioral tests, comparing single treatments of afzelin (10 or 100 ng of afzelin) in scopolamine-induced AD mice. AuNP-afzelin also performed superior neuroprotective effects of rescuing mature neuronal cells and recovered cholinergic dysfunction compared to afzelin alone, according to further investigations of BDNF-pCREB-pAkt signaling, long-term potentiation, and doublecortin (DCX) expression in the hippocampus. This study highlights the potential of afzelin with gold nanoparticles as a promising therapeutic approach for mitigating cognitive impairments associated with neurodegenerative diseases and offers a new avenue for future research and drug development.
- 20 February 2025
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 16 (5) , 826-843
Enhanced Cognitive and Memory Functions via Gold Nanoparticle-Mediated Delivery of Afzelin through Synaptic Modulation Pathways in Alzheimer’s Disease Mouse Models
Gold nanoparticles (AuNPs) are valuable tools in pharmacological and biological research, offering unique properties for drug delivery in the treatment of neurodegenerative diseases. This study investigates the potential of gold nanoparticles loaded with afzelin, a natural chemical extracted from Ribes fasciculatum, to enhance its therapeutic effects and overcome the limitations of using natural compounds regarding low productivity. We hypothesized that the combined treatment of AuNPs with afzelin (AuNP-afzelin) would remarkably enforce neuroprotective effects compared with the single treatment of afzelin. Central administration of AuNP-afzelin (10 ng of afzelin) indicated improvements in cognition and memory-involved assessments of behavioral tests, comparing single treatments of afzelin (10 or 100 ng of afzelin) in scopolamine-induced AD mice. AuNP-afzelin also performed superior neuroprotective effects of rescuing mature neuronal cells and recovered cholinergic dysfunction compared to afzelin alone, according to further investigations of BDNF-pCREB-pAkt signaling, long-term potentiation, and doublecortin (DCX) expression in the hippocampus. This study highlights the potential of afzelin with gold nanoparticles as a promising therapeutic approach for mitigating cognitive impairments associated with neurodegenerative diseases and offers a new avenue for future research and drug development.